Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease

Next Previous
Trial Profile

A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Charcot-Marie-Tooth disease
  • Focus Therapeutic Use
  • Acronyms COMMIT
  • Sponsors Flex Pharma

    • Most Recent Events

    • 13 Jun 2018 Status changed from recruiting to discontinued, because company is ending its ongoing Phase 2 clinical trial investigations of FLX-787 in Charcot-Marie-Tooth (CMT) due to oral tolerability concerns observed , in a subset of patients being treated, with the oral disintegrating tablet formulation at 30 mg, taken three times a day, according to a Flex Pharma media release.
    • 07 Mar 2018 According to a Flex Pharma media release, the Company expects to report topline data from this study in early 2019.
    • 06 Nov 2017 According to a Flex Pharma media release, the company expects to report topline results from this trial in the third quarter of 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top